Mankind Pharma and BDR Pharma come together to launch Molulife (Molnupiravir)
The tie-up is a licensing arrangement where production is by BDR Pharma and marketing, selling, promotion and distribution is by Mankind Pharma
Mankind Pharma and BDR Pharmaceuticals have launched oral anti-COVID pill Molulife (Molnupiravir). The tie-up is a licensing arrangement where production is by BDR Pharma and marketing, selling, promotion and distribution is by Mankind Pharma, the companies notified via a joint statement.
Developed by Merck & Co in collaboration with Ridgeback Biotherapeutics, it is the first oral anti-COVID pill approved by the UK’s drug regulator-UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 in adults.
Recently, the US Food and Drug Administration (FDA) issued an Emergency Use Authorisation (EUA) for Molnupiravir to treat mild-to-moderate COVID-19.
Apart from it, the Drugs Controller General of India (DCGI) also granted permission for restricted use of Molnupiravir under emergency situation for treatment of adult patients with SpO2 93% and who have high risk of progression of the disease.